The Alzheimer's disease neuroimaging initiative (ADNI): MRI methods
Mayo Clinic · National Hospital for Neurology and Neurosurgery · +17 more institutions
Abstract
The Alzheimer's Disease Neuroimaging Initiative (ADNI) is a longitudinal multisite observational study of healthy elders, mild cognitive impairment (MCI), and Alzheimer's disease. Magnetic resonance imaging (MRI), (18F)-fluorodeoxyglucose positron emission tomography (FDG PET), urine serum, and cerebrospinal fluid (CSF) biomarkers, as well as clinical/psychometric assessments are acquired at multiple time points. All data will be cross-linked and made available to the general scientific community. The purpose of this report is to describe the MRI methods employed in ADNI. The ADNI MRI core established specifications that guided protocol development. A major effort was devoted to evaluating 3D T(1)-weighted…
Citation impact
- FWCI
- 96.34
- Percentile
- 100%
- References
- 21
Authors
35Topics & keywords
- Neuroimaging
- Alzheimer's Disease Neuroimaging Initiative
- Magnetic resonance imaging
- Medicine
- Protocol (science)
- Nuclear medicine
- Radiology
- Alzheimer's disease
Funding
- FFFoundation for the National Institutes of HealthAwards: AG024904, U01 AG024904
- AAAlzheimer's AssociationAward: U01 AG024904
- BSBristol-Myers SquibbAwards: U01 AG024904, AG024904
- ELEli Lilly and CompanyAwards: U01 AG024904, AG024904
- PPfizerAwards: AG024904, U01 AG024904
- AAstraZeneca
- GGlaxoSmithKline
- ADAlzheimer's Disease Neuroimaging InitiativeAwards: AG024904, U01 AG024904
- NPNovartis Pharmaceuticals CorporationAwards: U01 AG024904, AG024904
- EElanAward: U01 AG024904
- EEisaiAwards: U01 AG024904, AG024904
- NINational Institutes of HealthAwards: AG024904, U01 AG024904
- UFU.S. Food and Drug Administration
- NINational Institute on AgingAwards: U01 AG024904, AG024904
- NINational Institute of Biomedical Imaging and BioengineeringAwards: U01 AG024904, AG024904